Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Aerobiology and pollution (40)
  • Allergen immunotherapy (81)
  • AllergoOncology (14)
  • Allergy asthma and a sport (4)
  • Allergy diagnosis (222)
  • Allied health and primary care (19)
  • Anaphylaxis (112)
  • Artificial Intelligence (12)
  • Asthma (138)
  • Basic immunology (57)
  • Biologicals (75)
  • Biomarkers (54)
  • Comparative veterinary allergology (1)
  • COVID19 (9)
  • Dermatology (123)
  • Drug allergy (158)
  • ENT (24)
  • Environmental allergy and climate change (30)
  • Eosinophilic esophagitis (21)
  • Epidemiology (64)
  • Epithelial cell biology (8)
  • Food allergy (193)
  • Genomics and proteomics (17)
  • Immune deficiencies and autoimmunity (77)
  • Immunomodulation and nutrition (13)
  • Infections (24)
  • Insect venom hypersensitivities (19)
  • Mastocytosis and mast cells (23)
  • Microbiome (8)
  • Occupational allergy (24)
  • Ocular allergy (5)
  • One Health (13)
  • Pediatrics (131)
  • Prevention (38)
  • Systems medicine (13)
Poster available until
  • Until platform closure (46)
Poster categories
  • x e-Thematic Poster Session (93)
  • x Thematic Poster Session (980)
keywords
Session Reference
  • L-TPS01 (11)
  • L-TPS02 (15)
  • L-TPS03 (14)
  • L-TPS04 (12)
  • L-TPS05 (13)
  • L-TPS06 (8)
  • L-TPS07 (11)
  • L-TPS08 (7)
  • L-TPS09 (13)
  • L-TPS10 (13)
  • L-TPS11 (12)
  • L-TPS12 (14)
  • L-TPS13 (13)
  • L-TPS14 (11)
  • L-TPS15 (7)
  • L-TPS16 (5)
  • L-TPS17 (13)
  • L-TPS18 (9)
  • L-TPS19 (10)
  • L-TPS20 (12)
  • L-TPS21 (12)
  • TPS01 (12)
  • TPS02 (8)
  • TPS03 (14)
  • TPS04 (9)
  • TPS05 (15)
  • TPS06 (11)
  • TPS07 (13)
  • TPS08 (9)
  • TPS09 (9)
  • TPS10 (16)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (15)
  • TPS16 (15)
  • TPS17 (12)
  • TPS18 (10)
  • TPS19 (7)
  • TPS20 (11)
  • TPS21 (5)
  • TPS22 (3)
  • TPS23 (4)
  • TPS25 (12)
  • TPS26 (14)
  • TPS27 (12)
  • TPS28 (16)
  • TPS29 (16)
  • TPS30 (14)
  • TPS31 (15)
  • TPS32 (16)
  • TPS33 (14)
  • TPS34 (17)
  • TPS35 (15)
  • TPS36 (12)
  • TPS37 (15)
  • TPS38 (13)
  • TPS39 (14)
  • TPS40 (13)
  • TPS41 (9)
  • TPS42 (12)
  • TPS43 (12)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (8)
  • TPS47 (7)
  • TPS48 (5)
  • TPS49 (5)
  • TPS51 (1)
  • TPS52 (12)
  • TPS53 (8)
  • TPS54 (15)
  • TPS55 (1)
  • TPS57 (11)
  • TPS58 (1)
  • TPS59 (12)
  • TPS60 (9)
  • TPS61 (1)
  • TPS62 (8)
  • TPS63 (10)
  • TPS64 (11)
  • TPS65 (7)
  • TPS66 (9)
  • TPS67 (9)
  • TPS68 (19)
  • TPS69 (8)
  • TPS70 (9)
  • TPS71 (11)
  • TPS72 (6)
  • TPS73 (5)
  • TPS75 (4)
1073 results
Thumbnail

D3.388 - Exome Sequencing Provides Critical Insights into Genetic Causes of Food Allergy

Thumbnail

D3.389 - Deep Learning-Based Real-Time Identification of Wheezing in Lung Sounds: Applications in Disease Prediction and Early Intervention

Thumbnail

D3.390 - Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)

Thumbnail

D3.391 - Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)

Thumbnail

D3.392 - What information and education is crucial for people with food allergies?

Thumbnail

D3.393 - Daily life with a peanut allergy, as a young adult- an interview study

Thumbnail

D3.394 - Anxiety Associated with Parenteral On-Demand Treatment for Hereditary Angioedema Attacks in Patients from Italy

Thumbnail

D3.395 - Evaluation for suspected penicillin allergy - the patient perspective

Thumbnail

D3.398 - Food provision experience of inpatients with adverse food reactions in the acute hospital setting

Thumbnail

D3.399 - Age-Dependent Manifestations of Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic esophagitis

Thumbnail

D3.402 - Potential role of Advanced Glycation End-products in Pediatric Eosinophilic Esophagitis

Thumbnail

D3.403 - Dupilumab improves multiple histopathologic features of eosinophilic esophagitis over 52 weeks: Post hoc analysis of the phase 3 LIBERTY EoE TREET study

Thumbnail

D3.404 - Disease induction in a mouse model of eosinophilic esophagitis is lymphocyte dependent

Thumbnail

D3.405 - Clinical Characteristics and Treatment Response of Eosinophilic Esophagitis in Pediatric Patients: A Descriptive Study from a High-Complexity Colombian Institution

Thumbnail

D3.406 - Experience of dupilumab in difficult-to-treat eosinophilic esophagitis - A Case Series of 6 Portuguese Patients

Thumbnail

D3.407 - Clinic-pathological characteristics and comorbidities in adult patients with eosinophilic esophagitis in Greece

Thumbnail

D3.409 - Eosinophilic esophagitis and hen's egg tolerance: two cases highlighting remission with strongly heated but not less heated hen's egg despite topical steroid treatment

Thumbnail

D3.410 - A concurrence of eosinophilic esophagitis and eosinophilic gastritis in a patient with hypereosinophillia

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Current page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • …
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM